Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on APTO. Canaccord Genuity Group lowered their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $14.80.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $0.49 on Friday. Aptose Biosciences has a 1 year low of $0.40 and a 1 year high of $4.70. The firm’s 50-day moving average is $0.66 and its two-hundred day moving average is $1.17. The firm has a market capitalization of $8.79 million, a PE ratio of -0.08 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.15. Analysts expect that Aptose Biosciences will post -2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.